🟢 Taysha Gene Therapies is trading 7.5% up in pre-market with no identified catalyst

Taysha Gene Therapies is trading at $4.31, up 7.52% in pre-market, with no specific catalyst identified.

• No new company announcement dated October 23 was identified; its latest listed release was the October 2 inducement-grant announcement.
• Recent coverage highlighted positive REVEAL trial findings but does not establish them as the cause of the move.
• Broader market signals are mixed, offering no clear same-direction explanation.